These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 1365644)

  • 1. Psychopharmacological properties of calcium channel inhibitors.
    Pucilowski O
    Psychopharmacology (Berl); 1992; 109(1-2):12-29. PubMed ID: 1365644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacological properties of calcium channel blockers and the outlook for their use in psychiatry and neurology].
    Kozlovskiĭ VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(1):104-8. PubMed ID: 8009924
    [No Abstract]   [Full Text] [Related]  

  • 3. [Central effect of Ca2+ channel blockers: multiple sites of action].
    Shibuya T; Watanabe Y
    Nihon Yakurigaku Zasshi; 1992 Sep; 100(3):239-47. PubMed ID: 1398335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcium antagonistic actions of drugs used in treatment of affective disorders].
    Langosch JM; Walden J
    Fortschr Neurol Psychiatr; 1998 Dec; 66(12):570-9. PubMed ID: 9922929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological profiles of calcium antagonists.
    Soubrie P
    Fundam Clin Pharmacol; 1989; 3 Suppl():71s-78s. PubMed ID: 2693293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voltage-operated calcium channels: characteristics and their role in the mechanism of action of psychotropic drugs.
    Antkiewicz-Michaluk L
    Pol J Pharmacol; 1999; 51(2):179-86. PubMed ID: 10425648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mg2+-Ca2+ interaction in contractility of vascular smooth muscle: Mg2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels.
    Altura BM; Altura BT; Carella A; Gebrewold A; Murakawa T; Nishio A
    Can J Physiol Pharmacol; 1987 Apr; 65(4):729-45. PubMed ID: 3300911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium, calcium channels, and calcium channel antagonists.
    Triggle DJ
    Can J Physiol Pharmacol; 1990 Nov; 68(11):1474-81. PubMed ID: 1962736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists.
    Liu H; Enyeart JA; Enyeart JJ
    J Pharmacol Exp Ther; 2007 Oct; 323(1):39-48. PubMed ID: 17622574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channels and calcium channel antagonists.
    Greenberg DA
    Ann Neurol; 1987 Apr; 21(4):317-30. PubMed ID: 2437852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: effects of bifemelane and several nootropic agents.
    Kaneko S; Takahashi H; Satoh M
    Eur J Pharmacol; 1990 Jul; 189(1):51-8. PubMed ID: 2171962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium channel blockers (calcium antagonists). Background, effects and use].
    Mikkelsen EO
    Ugeskr Laeger; 1995 Jun; 157(26):3750-4. PubMed ID: 7631450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release.
    Waldmeier PC; Wicki P; Fröstl W; Bittiger H; Feldtrauer JJ; Baumann PA
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Dec; 352(6):670-8. PubMed ID: 9053740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology].
    Bespalov AIu; Evartau EE
    Usp Fiziol Nauk; 1999; 30(1):39-53. PubMed ID: 10205818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sites of action of Ca2+ channel inhibitors.
    Janis RA; Scriabine A
    Biochem Pharmacol; 1983 Dec; 32(23):3499-507. PubMed ID: 6360175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular effects of calcium channel antagonists: new evidence.
    Richard S
    Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CA3 GABA
    Zarrabian S; Nasehi M; Farrahizadeh M; Zarrindast MR
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):515-524. PubMed ID: 28800869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists.
    Apostolakos MJ; Varon ME
    New Horiz; 1996 Feb; 4(1):45-57. PubMed ID: 8689275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological basis of Ca2+ channels and Ca2+ channel antagonists].
    Adachi-Akahane S
    Clin Calcium; 2005 Oct; 15(10):1589-97. PubMed ID: 16199903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.